Core Insights - Charles River Laboratories (CRL) reported revenue of $984.17 million for Q1 2025, reflecting a year-over-year decline of 2.7% but exceeding the Zacks Consensus Estimate by 5.25% [1] - The earnings per share (EPS) for the same quarter was $2.34, up from $2.27 a year ago, representing a surprise of 13.59% over the consensus estimate of $2.06 [1] Revenue Breakdown - Revenue from Research Models and Services was $213.07 million, surpassing the average estimate of $207.28 million, with a year-over-year change of -3.6% [4] - Revenue from Discovery and Safety Assessment reached $592.61 million, exceeding the average estimate of $545.81 million, with a year-over-year decline of -2.1% [4] - Revenue from Manufacturing Solutions was $178.49 million, slightly below the average estimate of $182.94 million, showing a year-over-year change of -3.6% [4] - Revenue from Services totaled $797.92 million, exceeding the average estimate of $755.46 million, with a year-over-year decline of -2.3% [4] - Revenue from Products was $186.25 million, above the average estimate of $178.87 million, reflecting a year-over-year change of -4.3% [4] Operating Income Analysis - Non-GAAP operating income for Research Models and Services was $57.73 million, exceeding the average estimate of $46.59 million [4] - Non-GAAP operating income for Discovery and Safety Assessment was $141.70 million, surpassing the average estimate of $122.57 million [4] - Non-GAAP operating income for Manufacturing Solutions was -$8.62 million, significantly below the average estimate of $41.50 million [4] - Unallocated Corporate Overhead reported an operating income of -$54.27 million, better than the average estimate of -$59.34 million [4] Stock Performance - Over the past month, shares of Charles River have returned -6.6%, contrasting with the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - RXO reported revenue of $1.43 billion for the quarter ended March 2025, reflecting a 57% increase year-over-year, although it fell short of the Zacks Consensus Estimate of $1.5 billion by 4.74% [1] - The company’s EPS was -$0.03, unchanged from the same quarter last year, and it missed the consensus EPS estimate of -$0.02 by 50% [1] Revenue Breakdown - Revenue from Truck Brokerage was $1.07 billion, below the average estimate of $1.17 billion [4] - Revenue from Complementary Services reached $415 million, exceeding the average estimate of $391.86 million [4] - Managed Transportation revenue was $137 million, slightly above the average estimate of $134.98 million [4] - Last Mile revenue was $278 million, surpassing the average estimate of $246.33 million [4] - Eliminations amounted to -$49 million, worse than the average estimate of -$35.08 million [4] Gross Margin Analysis - Gross margin for Complementary Services was $87 million, exceeding the average estimate of $83.43 million [4] - Gross margin for Truck Brokerage was $142 million, slightly below the average estimate of $145.10 million [4] Stock Performance - RXO shares have returned +6.3% over the past month, underperforming the Zacks S&P 500 composite's +10.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Coty reported $1.3 billion in revenue for the quarter ended March 2025, reflecting a year-over-year decline of 6.2% and an EPS of $0.01 compared to $0.05 a year ago, indicating a significant drop in earnings [1] - The revenue fell short of the Zacks Consensus Estimate by -0.43%, while the EPS surprise was -80.00% against the consensus estimate of $0.05 [1] Financial Performance Metrics - Coty's shares returned +5.3% over the past month, underperforming the Zacks S&P 500 composite's +11.5% change, with a Zacks Rank 4 (Sell) suggesting potential underperformance in the near term [3] - Geographic revenues showed varied performance: - Americas: $529.70 million, down -10.1% year-over-year and below the estimated $546.01 million [4] - Asia Pacific: $159.40 million, a -5.5% change year-over-year, exceeding the estimate of $146.69 million [4] - EMEA: $610 million, a -2.9% change year-over-year, slightly below the estimate of $617.96 million [4] - Net revenues by segment: - Prestige: $829.40 million, down -4.4% year-over-year, slightly below the estimate of $833.25 million [4] - Consumer Beauty: $469.70 million, down -9.4% year-over-year, also below the estimate of $471.58 million [4] - Adjusted Operating Income (Loss) metrics: - Consumer Beauty: -$10.90 million, better than the estimate of -$11.85 million [4] - Prestige: $158.80 million, exceeding the estimate of $141.62 million [4] - Corporate: -$169.60 million, significantly worse than the estimate of -$69.77 million [4]

Core Insights - Henry Schein reported $3.17 billion in revenue for Q1 2025, a slight year-over-year decline of 0.1% [1] - The EPS for the quarter was $1.15, up from $1.10 a year ago, indicating a positive trend in earnings [1] - The revenue fell short of the Zacks Consensus Estimate of $3.23 billion by 1.84%, while the EPS exceeded the consensus estimate of $1.11 by 3.60% [1] Revenue Performance - Geographic Revenue from International Dental Equipment was $197 million, below the average estimate of $209.20 million [4] - U.S. Distribution Revenue for Dental Equipment was $187 million, significantly lower than the estimated $232.79 million, reflecting a 25.4% decline year-over-year [4] - International Dental Merchandise revenue was $594 million, also below the estimate of $608.26 million [4] - U.S. Distribution Medical revenue was $1.03 billion, slightly above the estimate of $1.01 billion, showing a year-over-year increase of 1.6% [4] - International Dental revenue was $798 million, under the estimate of $824.47 million, with a year-over-year decline of 1.6% [4] - U.S. Distribution Dental Merchandise revenue was $591 million, exceeding the estimate of $569.68 million [4] - Global Specialty Products net sales were $367 million, slightly above the average estimate of $364.59 million [4] Stock Performance - Henry Schein's shares returned -0.3% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

In its upcoming report, Texas Roadhouse (TXRH) is predicted by Wall Street analysts to post quarterly earnings of $1.75 per share, reflecting an increase of 3.6% compared to the same period last year. Revenues are forecasted to be $1.44 billion, representing a year-over-year increase of 9%.Over the last 30 days, there has been a downward revision of 1.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their init ...

Core Insights - ICF International reported a revenue of $487.62 million for the quarter ended March 2025, reflecting a decrease of 1.4% year-over-year, while EPS increased to $1.94 from $1.77 in the previous year [1] - The revenue was slightly below the Zacks Consensus Estimate of $487.7 million, resulting in a surprise of -0.02%, whereas the EPS exceeded the consensus estimate of $1.74 by +11.49% [1] Revenue Breakdown - Revenue from the US Federal government was $239.62 million, surpassing the average estimate of $236.82 million from two analysts [4] - Revenue from US State & Local government was $76.87 million, falling short of the average estimate of $86.85 million from two analysts [4] - Commercial revenue reached $144.06 million, exceeding the average estimate of $132.40 million from two analysts [4] - Total revenue from the Government sector was $343.56 million, slightly below the average estimate of $351.86 million from two analysts [4] - International government revenue was $27.08 million, also below the average estimate of $28.19 million from two analysts [4] Stock Performance - ICF shares have returned +1.5% over the past month, contrasting with a -0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - RE/MAX reported revenue of $74.47 million for the quarter ended March 2025, reflecting a year-over-year decline of 4.9% [1] - The company's EPS for the same period was $0.24, an increase from $0.20 a year ago, resulting in an EPS surprise of +33.33% compared to the consensus estimate of $0.18 [1] Revenue Breakdown - Marketing Funds fees amounted to $18.86 million, exceeding the two-analyst average estimate of $18.10 million, but showing a year-over-year decline of 6.6% [4] - Continuing franchise fees were reported at $29.35 million, slightly above the estimated $29.32 million, with a year-over-year decrease of 5.6% [4] - Franchise sales and other revenue totaled $7.03 million, below the average estimate of $7.99 million, marking a year-over-year decline of 12.7% [4] - Broker fees reached $11.43 million, surpassing the estimated $11.12 million, and showing a year-over-year increase of 6.7% [4] - Annual dues were reported at $7.79 million, slightly below the average estimate of $8.02 million, with a year-over-year decline of 5.3% [4] Stock Performance - Over the past month, RE/MAX shares have returned -8.7%, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Ingersoll Rand reported $1.72 billion in revenue for Q1 2025, a year-over-year increase of 2.8%, but fell short of the Zacks Consensus Estimate by 1.00% [1] - The company's EPS for the quarter was $0.72, down from $0.78 a year ago, representing an EPS surprise of -1.37% compared to the consensus estimate of $0.73 [1] Revenue Performance - Precision and Science Technologies revenue was $364.70 million, exceeding the estimated $364.25 million, reflecting a year-over-year increase of 22.9% [4] - Industrial Technologies and Services revenue was reported at $1.35 billion, slightly below the $1.37 billion estimate, showing a year-over-year decline of 1.6% [4] EBITDA Analysis - Adjusted EBITDA for Precision & Science Technologies was $106.20 million, surpassing the average estimate of $103.89 million [4] - Adjusted EBITDA for Industrial Technologies & Services was $389.10 million, which was below the estimated $406.83 million [4] Stock Performance - Ingersoll Rand's shares have returned -7.7% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - CVS Health reported revenue of $94.59 billion for the quarter ended March 2025, marking a year-over-year increase of 7% and exceeding the Zacks Consensus Estimate of $92.95 billion by 1.76% [1] - The company achieved an EPS of $2.25, up from $1.31 a year ago, resulting in an EPS surprise of 31.58% compared to the consensus estimate of $1.71 [1] Financial Metrics - Medical benefit ratio (MBR) was reported at 87.3%, lower than the average estimate of 88.6% [4] - Total medical membership reached 27.08 million, surpassing the average estimate of 25.99 million [4] - Revenue from Health Care Benefits was $34.81 billion, exceeding the average estimate of $33.66 billion, reflecting an 8% year-over-year increase [4] - Revenue from the Pharmacy & Consumer Wellness Segment was $31.91 billion, above the average estimate of $31.20 billion, with an 11.1% year-over-year increase [4] - Net revenue from the Health Services segment was $40.12 billion, below the average estimate of $43.36 billion, showing a slight decline of 0.4% year-over-year [4] - Pharmacy claims processed totaled 464.2 million, slightly below the average estimate of 467.42 million [4] - Revenue from the Pharmacy segment was $26.08 billion, exceeding the average estimate of $25.29 billion, with a year-over-year increase of 14.5% [4] - Revenue from the front store of the Pharmacy & Consumer Wellness Segment was $5.24 billion, below the average estimate of $5.43 billion, reflecting a decline of 2.4% year-over-year [4] - Net investment income in the Health Care Benefits Segment was $387 million, surpassing the average estimate of $297.44 million, representing a 9.6% year-over-year increase [4] - Revenue from services in the Health Care Benefits Segment was $1.62 billion, slightly above the average estimate of $1.60 billion, with a year-over-year increase of 7.4% [4] Stock Performance - CVS Health shares have returned -2% over the past month, compared to a -0.7% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Parsons (PSN) reported revenue of $1.55 billion for the quarter ended March 2025, reflecting a 1.2% increase year-over-year, but a -3.45% miss against the Zacks Consensus Estimate of $1.61 billion [1] - The company's EPS was $0.78, up from $0.70 in the same quarter last year, resulting in a +5.41% surprise compared to the consensus estimate of $0.74 [1] Revenue Performance - Critical Infrastructure revenue was $711.80 million, exceeding the estimated $704.86 million, marking a +13.7% change from the previous year [4] - Federal Solutions revenue was $842.56 million, below the estimated $894.52 million, representing a -7.4% change year-over-year [4] EBITDA Analysis - Adjusted EBITDA for Critical Infrastructure was $73.19 million, surpassing the average estimate of $59.15 million from two analysts [4] - Adjusted EBITDA for Federal Solutions was $75.58 million, slightly below the estimated $79.70 million from two analysts [4] Stock Performance - Shares of Parsons have returned +15.3% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]